이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

TECAR Therapy in Chronic Back Pain

2026년 9월 9일 업데이트: Richard Liebano, University of Hartford

An Investigation Into the Short-term Effects of Capacitive and Resistive Electrical Transfer Therapy Alone Versus Combined With Electrical Stimulation in Chronic Low Back Pain.

The goal of this clinical trial is to learn whether adding high-intensity electromyostimulation (Hi-EMS) to capacitive and resistive electric transfer (TECAR) therapy improves pain and functional performance in adults with chronic nonspecific low back pain. The main questions it aims to answer are:

  • Does adding Hi-EMS to TECAR therapy reduce low back pain at rest?
  • Does adding Hi-EMS reduce pain during the Five-Times-Sit-to-Stand Test?
  • Does adding Hi-EMS improve pressure pain threshold and performance on the - Five-Times-Sit-to-Stand Test?

Researchers will compare TECAR therapy delivered with Hi-EMS to TECAR therapy delivered without Hi-EMS.

Participants will:

  • Receive both treatment conditions in a randomized order
  • Wait one week between treatment sessions
  • Receive 10 minutes of capacitive electrical transfer followed by 10 minutes of resistive electrical transfer during each session
  • Receive Hi-EMS during the 10-minute resistive electrical transfer phase in one of the sessions
  • Complete pain, pressure pain threshold, and functional performance assessments immediately before and after each session

연구 개요

상세 설명

Capacitive and resistive electric transfer (TECAR) therapy is a radiofrequency-based electrothermal modality designed to generate endogenous tissue heating. Preliminary evidence suggests that TECAR therapy may provide short-term improvements in pain and disability in individuals with low back pain. Some TECAR devices also incorporate a manufacturer-specific electrical stimulation function known as high-intensity electromyostimulation (Hi-EMS). However, the additional effects of combining Hi-EMS with TECAR therapy have not been established.

This randomized, assessor-blinded crossover trial will investigate whether adding Hi-EMS to TECAR therapy produces greater immediate improvements in pain and functional performance than TECAR therapy alone in individuals with chronic nonspecific low back pain. Each participant will receive both treatment conditions in a randomized order, allowing participants to serve as their own controls. The treatment sessions will be separated by a one-week washout period.

The study will evaluate immediate within-session responses and compare the magnitude of change between the two treatment conditions. The findings will help determine whether the concurrent use of Hi-EMS provides additional short-term benefits beyond those produced by TECAR therapy alone.

연구 유형

중재적

등록 (추정된)

37

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion criteria:

  • 21 to 60 years old
  • chronic nonspecific low back pain
  • minimum pain intensity of 3 on a 0-10 scale
  • be able to provide consent and comply with study procedures

Exclusion criteria:

  • spinal fracture
  • tumor
  • radiculopathy
  • neurological or vascular condition
  • pregnancy
  • cardiac pacemaker or other implanted device
  • skin disorder or allergy
  • altered sensation in the treatment area
  • active or recent hemorrhage
  • cognitive impairments
  • liniments or heat rubs immediately before a study session
  • treatment for low back within the previous 6 weeks
  • currently receiving disability benefits because of low back pain
  • current or pending litigation related to low back pain

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 하나의

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: TECAR Therapy Plus Hi-EMS
Participants will receive TECAR therapy with concurrent Hi-EMS. The intervention will consist of 10 minutes of capacitive electrical transfer followed by 10 minutes of resistive electrical transfer, with Hi-EMS delivered only during the 10-minute resistive electrical transfer phase.
TECAR therapy will be delivered using the BACK4 system (Winback Europa SAS, Biarritz, France). The intervention will consist of 10 minutes of capacitive electrical transfer (CET) followed by 10 minutes of resistive electrical transfer (RET). A conductive cream will be applied to the treatment area, and a return plate will be positioned over the abdomen. The Hi-EMS Focal mode will be activated only during the 10-minute RET phase and adjusted to produce a strong but comfortable stimulation without pain or excessive discomfort.
활성 비교기: TECAR Therapy Alone
Participants will receive TECAR therapy without Hi-EMS. The intervention will consist of 10 minutes of capacitive electrical transfer followed by 10 minutes of resistive electrical transfer.
TECAR therapy will be delivered using the BACK4 system (Winback Europa SAS, Biarritz, France). The intervention will consist of 10 minutes of capacitive electrical transfer (CET) followed by followed by 10 minutes of resistive electrical transfer (RET). A conductive cream will be applied to the treatment area, and a return plate will be positioned over the abdomen. Hi-EMS will not be activated during this condition.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Pain intensity at rest
기간: Immediately before and immediately after each treatment session
Low back pain intensity at rest will be assessed using an 11-point Numerical Pain Rating Scale (NPRS), ranging from 0 ("no pain") to 10 ("worst pain imaginable"). Participants will rate their current low back pain while at rest before performing the functional test. Higher scores indicate greater pain intensity.
Immediately before and immediately after each treatment session
Movement-Evoked Pain Intensity
기간: Immediately before and immediately after each treatment session.
Movement-evoked low back pain intensity will be assessed immediately after the Five-Times-Sit-to-Stand Test using an 11-point Numerical Pain Rating Scale (NPRS), ranging from 0 ("no pain") to 10 ("worst pain imaginable"). Participants will rate the greatest low back pain experienced while performing the test. Higher scores indicate greater pain intensity.
Immediately before and immediately after each treatment session.

2차 결과 측정

결과 측정
측정값 설명
기간
Pressure pain threshold
기간: Immediately before and immediately after each treatment session.
A computerized digital pressure algometer (AlgoMed, Medoc Ltd.) with a 1-cm² probe will assess lumbar pressure pain threshold (PPT). Pressure will be applied at 40 kPa/s, and participants will press a response button when the sensation first becomes painful. PPT will be measured three times bilaterally at sites 5 cm lateral to the L3 and L5 spinous processes, with 30-second intervals. The measurements will be averaged to obtain a single lumbar PPT value at each assessment.
Immediately before and immediately after each treatment session.
Five-Times-Sit-to-Stand Test
기간: Immediately before and immediately after each treatment session.
Functional performance will be assessed using the Five-Times-Sit-to-Stand Test. Participants will be instructed to complete five consecutive sit-to-stand repetitions as quickly and safely as possible. The time required to complete five repetitions will be measured using a stopwatch. The test will be performed twice, and the mean completion time of the two trials will be used for analysis.
Immediately before and immediately after each treatment session.

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 10월 19일

기본 완료 (추정된)

2027년 2월 9일

연구 완료 (추정된)

2027년 2월 9일

연구 등록 날짜

최초 제출

2026년 9월 9일

QC 기준을 충족하는 최초 제출

2026년 9월 9일

처음 게시됨 (실제)

2026년 9월 15일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 15일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 9일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

IPD sharing is not currently planned because a data-sharing process and repository have not been established for this study.

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다